Bevacizumab as front-line treatment of brain metastases from solid tumors: A case series

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 4061-4066

  Zustovich, Fable ^a   Ferro, Alessandra ^a   Lombardi, Giuseppe ^a   Zagonel, Vittorina ^a   Fiduccia, Pasquale ^a   Farina, Patrizia ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Bevacizumab; Brain; Cancer; Chemotherapy; Interferon ; Kidney; Lung; Metastasis

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CISPLATIN; GEMCITABINE;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN ISCHEMIA; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; EDEMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LOCAL THERAPY; LUNG ADENOCARCINOMA; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NEUROSURGERY; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOLID TUMOR; STEREOTAXIC SURGERY; STOMACH PERFORATION; TREATMENT RESPONSE;

BEVACIZUMAB; BRAIN; CANCER; CHEMOTHERAPY; INTERFERON-Α; KIDNEY; LUNG; METASTASIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84885003143     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY and Jain RK: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145-147, 2004.
2. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307: 58-62, 2005.
3. Nayak L, Lee EQ, Wen PY: Epidemiology of brain metastases. Curr Oncol Rep 14(1): 48-54, 2012.
4. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG and Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4): 745-51, 1997.
5. Chamberlain MC: Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 5: 117-129, 2011.
6. Hapani S, Sher A, Chu D and Wu S: Increased risk of serious hemorrhage with bevacizumab in cancer patients: A metaanalysis. Oncology 79: 27-38, 2010.
7. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L and Akerley W: Safety of bevacizumab in patients with non-small cell lung cancer and brain metastases. J Clin Oncol 27: 5255-5261, 2009.
8. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8. 5x11.pdf
9. http://www.recist.com/recist-in-practice/01.html
10. Zustovich F, Lombardi G, Pastorelli D, Farina P, Furini L, Manara R, Dalla Palma M, Rotilio A, Nicoletto O and Zagonel V: Bevacizumab and glioblastomas, a single-centre experience: How disease history and characteristics may affect clinical outcome. Anticancer Res 30(12): 5213-5216, 2010.
11. Dhami MS, Bona RD, Calogero JA and Helman RM: Venous thromboembolism and high-grade gliomas. Thromb Haemost 3: 393-396, 1993.
12. Schutz FA, Je Y, Azzi GR, Nguyen PL and Choueiri TK: Bevacizumab increases the risk of arterial ischemia: A large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 22(6): 1404-1412, 2011.
13. Bhaskara A, Eng C: Bevacizumab in the Treatment of a Patient with Metastatic Colorectal Carcinoma with Brain Metastases. Clinical Colorectal Cancer 7: 65-68, 2008.
14. Labidi SI, Bachelot T, Ray-Coquard I, Mosbah K, Treilleux I, Fayette J, Favier B, Galy G, Blay JY and Guastalla JP: Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: A case series. Clin Breast Cancer 9(2): 118-121, 2009.
15. De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, Omuro AM, Holodny AI and Lassman AB: Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol 100(3): 443-447, 2010.
16. Yen-Shen L, Wei-Wu C, Ching-Hung L, Ling-Ming T, Dah-Cherng Y, Pei-Fang W, Bang-Bin C, Ta-Chung C, Yi-Fang T, Shu-Min H, Tiffany Ting-Fang S and Ann-Lii C: Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of breast cancer progressing from radiotherapy: Results of the first stage of a multicenter phase II study. J Clin Oncol 30, 2012 (suppl; abstr 1079).